The Countdown country profiles present in one place the latest evidence to assess country progress in improving women’s, children’s and adolescents’ health. The profiles, including an interactive version of them and all associated data, can be found by viewing the latest country profile data.
This document was developed by the Ministry of Health in Malawi in collaboration with national and international partners. It introduces a Social and Behaviour Change (SBC) malaria message guide that is aligned with the National Malaria Communication Strategy (NMCS) for the period 2023–2030. The g...uide aims to facilitate effective communication and behavioural change in order to reduce malaria-related morbidity and mortality. It provides a reference framework for messaging and communication tools tailored to target groups, supporting the broader goals of the Health Sector Strategic Plan III. This guide was developed with technical and financial support from key partners, including USAID, PMI through Breakthrough ACTION, and other stakeholders. The guide reflects Malawi’s ongoing commitment to evidence-based SBC interventions, community engagement, and the national fight against malaria.
more
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el
mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este
antirretrovírico en las poblaciones tratadas con esquemas que lo conti...enen. Si bien no se ha detectado resistencia
al dolutegravir en los ensayos clínicos con poblaciones no tratadas antes con antirretrovíricos en las que se ha
detectado una viremia persistente pese al tratamiento, los datos indican que puede surgir en quienes toman esquemas
con dolutegravir. La OMS recomienda a los países que estén ampliando el tratamiento con dolutegravir que acompañen
su despliegue con la vigilancia sistemática de la farmacorresistencia.
more
This report outlines the Ministry of Health’s National Health Research Agenda in which it identifies research priorities in health. It will be implemented in the same time frame as the Health Sector Strategic Plain 2012-2018. The Ministry of Health being the implementing agency of this document, i...s calling upon all partners, relevant ministries, higher learning institutions, students, development partners, etc to embrace this research agenda and ensure that researches conducted in Rwanda address priority areas identifies.
more
Regional Analysis. WPSAR Vol 7, No 2, 2016 | doi: 10.5365/wpsar.2015.6.4.010
The Infection Prevention and Control (IPC) Assessment Framework (IPCAF) is a tool to support the implementation of the World Health Organization (WHO) Guidelines on core components of IPC programmes at the acute health care facility level. The user should be familiar with the contents of these guide...lines, including the Interim practical manual supporting the implementation of the IPC core components at the facility level before using this tool. The IPCAF is a systematic tool that can provide a baseline assessment of the IPC programme and activities within a health care facility, as well as ongoing evaluations through repeated administration to document progress over time and facilitate improvement.
more
9 June 2021
Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth G...LASS report.
The fourth GLASS report summarizes the 2019 data reported to WHO in 2020. It includes data on AMC surveillance from 15 countries and AMR data on 3 106 602 laboratory-confirmed infections reported by 24 803 surveillance sites in 70 countries, compared to the 507 923 infections and 729 surveillance sites reporting to the first data call in 2017.
The report also describes developments over the past years of GLASS and other AMR surveillance programmes led by WHO, including resistance to anti-human immunodeficiency virus and anti-tuberculosis medicines, antimalarial drug efficacy.
more